Open AccessTotal Neoadjuvant Therapy With FOLFIRINOX Followed by Individualized Chemoradiotherapy for Borderline Resectable Pancreatic Adenocarcinoma
Author(s) -
Janet E. Murphy,
Jennifer Y. Wo,
David P. Ryan,
Wenqing Jiang,
Beow Y. Yeap,
Lorraine C. Drapek,
Lawrence S. Blaszkowsky,
Eunice L. Kwak,
Jill N. Allen,
Jeffrey W. Clark,
Jason E. Faris,
Andrew X. Zhu,
Lipika Goyal,
Keith D. Lillemoe,
Thomas F. DeLaney,
Carlos Fernándezdel Castillo,
Cristina R. Ferrone,
Theodore S. Hong
Publication year - 2018
Publication title -
jama oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 8.846
H-Index - 99
eISSN - 2374-2445
pISSN - 2374-2437
DOI - 10.1001/jamaoncol.2018.0329
Subject(s) - medicine , folfirinox , capecitabine , oxaliplatin , irinotecan , chemoradiotherapy , neoadjuvant therapy , fluorouracil , oncology , pancreatic cancer , adenocarcinoma , surgery , chemotherapy , colorectal cancer , cancer , breast cancer
Patients with borderline-resectable pancreatic ductal adenocarcinoma have historically poor outcomes with surgery followed by adjuvant chemotherapy. Evaluation of a total neoadjuvant approach with highly active therapy is warranted.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom